The escalating conflict in the Middle East has, thus far, not significantly disrupted global pharmaceutical supply chains. While key shipping and air routes are experiencing turbulence, experts suggest the immediate impact is contained, though the situation remains fluid and could change if the conflict persists or expands. The potential for increased costs and logistical challenges looms, particularly for companies reliant on routes through the region.
Currently, the immediate region accounts for a small fraction of global pharmaceutical production. According to the U.S. Pharmacopeia, an independent organization that develops standards for medicines and tracks global supplies, only 0.3% of the world’s medicines and 0.6% of active pharmaceutical ingredients are produced in the immediate conflict zone. This limited local production mitigates the risk of immediate widespread shortages, but the disruption to vital transportation corridors is a growing concern.
The primary impact is being felt in the disruption of critical shipping and air routes. Manufacturers, especially those based in India and the European Union, are facing the need to find alternative transportation pathways due to closures in the Strait of Hormuz and restrictions at major air hubs. These reroutings inevitably add to expenses, which could ultimately be passed on to consumers.
Shipping and Air Cargo Disruptions
The conflict has triggered delays across global supply chains, with commercial activity through the Strait of Hormuz currently 90% below pre-war levels as of March 16, 2026. Global air-cargo capacity in the Gulf region dropped 79% between February 28 and March 3, resulting in a 22% reduction worldwide, according to recent reports. This impacts the transport of critical medicines, particularly those requiring temperature-controlled handling.
Drugmakers are actively seeking unconventional routes to maintain the flow of products. These include utilizing land routes to truck cargo between airports in the Gulf Cooperation Council (GCC) region, or diverting air cargo to hubs in China or Singapore to bypass the conflict zone entirely. While these measures aim to prevent interruptions, they come at a cost. Experts warn that consumers could notice drug costs affected within four to six weeks due to increased Indian air-cargo rates.
Cold Chain Challenges and Vulnerable Medications
The disruption is particularly concerning for temperature-sensitive medications, including biologics, cancer therapies, and vaccines. Pharmaceutical Commerce reports that rerouting shipments increases transit duration and reliance on dry ice, raising the probability of temperature excursions – deviations from the required temperature range – which can compromise medication efficacy.
Inventory buffers in Gulf markets are typically around three months, but some buyers anticipate potential stockouts within four to six weeks if constraints persist. Beyond the active pharmaceutical ingredients, disruptions to the supply of packaging components, such as vial stoppers and IV bag plastics, could also create secondary shortages.
Long-Term Implications and the Need for Diversification
While immediate medicine shortages in the United States are considered unlikely due to extensive inventory buffers and largely uninterrupted Suez Canal shipping flows, the conflict highlights vulnerabilities in the pharmaceutical supply chain. A key takeaway is the dependence on specific transport hubs and the fragility of cold chains. Think Global Health suggests the need for a longer-term investment in the diversification and streamlining of pharmaceutical supply chains.
The situation underscores the need for improved visibility of supply-chain gaps and proactive risk management. Some experts are advocating for a standing Group of 20 (G20) coordination mechanism on pharmaceutical supply chains to manage risks during conflicts and support the production and distribution of medical countermeasures during health emergencies. Pharmaceutical Executive notes the ongoing need for leadership within the pharmaceutical industry to navigate these challenges.
Looking ahead, the duration and scope of the conflict will be critical in determining the long-term impact on pharmaceutical supply chains. Continued monitoring of shipping routes, air cargo capacity, and inventory levels will be essential to mitigate potential disruptions and ensure access to vital medications.
What we have is a developing situation, and we encourage readers to share their perspectives and experiences in the comments below.
Disclaimer: This article provides informational content only and is not intended to be a substitute for professional medical or financial advice.
